David Malcom Rodman, Chief Medical Officer at Mineralys Therapeutics, Inc. (MLYS), sold 417 shares at $27.55 ($11K) on 2026-05-18, disclosed to the SEC on 2026-05-19.
Scheduled sale ($11k) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| MLYS | SELL | 2026-07-15 | $557K | — | Filing → |
| MLYS | SELL | 2026-07-10 | $66K | — | Filing → |
| MLYS | SELL | 2026-06-17 | $350K | — | Filing → |